JP2005526727A5 - - Google Patents

Download PDF

Info

Publication number
JP2005526727A5
JP2005526727A5 JP2003569178A JP2003569178A JP2005526727A5 JP 2005526727 A5 JP2005526727 A5 JP 2005526727A5 JP 2003569178 A JP2003569178 A JP 2003569178A JP 2003569178 A JP2003569178 A JP 2003569178A JP 2005526727 A5 JP2005526727 A5 JP 2005526727A5
Authority
JP
Japan
Prior art keywords
liposome
lipid
acid
active substance
spacer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2003569178A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005526727A (ja
Filing date
Publication date
Priority claimed from DE10207177A external-priority patent/DE10207177A1/de
Application filed filed Critical
Publication of JP2005526727A publication Critical patent/JP2005526727A/ja
Publication of JP2005526727A5 publication Critical patent/JP2005526727A5/ja
Abandoned legal-status Critical Current

Links

JP2003569178A 2002-02-19 2003-02-19 ｐＨ感受性カチオン脂質、それを含有するリポソーム及びナノカプセル Abandoned JP2005526727A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10207177A DE10207177A1 (de) 2002-02-19 2002-02-19 Fakultativ kationische Lipide
PCT/EP2003/001661 WO2003070220A1 (de) 2002-02-19 2003-02-19 Ph sensitiv kationische lipide, lipsomen und nanokapseln, die diese umfassen

Publications (2)

Publication Number Publication Date
JP2005526727A JP2005526727A (ja) 2005-09-08
JP2005526727A5 true JP2005526727A5 (https=) 2006-04-06

Family

ID=27674784

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003569178A Abandoned JP2005526727A (ja) 2002-02-19 2003-02-19 ｐＨ感受性カチオン脂質、それを含有するリポソーム及びナノカプセル

Country Status (6)

Country Link
US (1) US8192753B2 (https=)
EP (1) EP1480621A1 (https=)
JP (1) JP2005526727A (https=)
AU (1) AU2003210303A1 (https=)
DE (1) DE10207177A1 (https=)
WO (1) WO2003070220A1 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2487274A1 (en) * 2002-05-06 2003-11-13 Nucleonics Inc. Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent
US20050191344A1 (en) * 2004-01-15 2005-09-01 Samuel Zalipsky Liposome composition for delivery of therapeutic agents
US20080088046A1 (en) * 2006-10-13 2008-04-17 Steffen Panzner Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome
AU2006291429B2 (en) 2005-09-15 2013-04-04 Biontech Delivery Technologies Gmbh Improvements in or relating to amphoteric liposomes
CN101346393B (zh) 2005-11-02 2015-07-22 普洛体维生物治疗公司 修饰的siRNA分子及其应用
PL1957044T3 (pl) * 2005-12-01 2013-11-29 Pronai Therapeutics Inc Amfoteryczny preparat liposomowy
NZ569138A (en) 2005-12-15 2012-06-29 Centre Nat Rech Scient Cationic oligonucleotides automated methods for preparing same and their uses
EP1844772A1 (en) 2006-04-06 2007-10-17 Polyplus-Transfection SA Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications
CA2665783C (en) 2006-10-13 2015-12-15 Novosom Ag Improvements in or relating to amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome
WO2008074487A2 (en) * 2006-12-19 2008-06-26 Novosom Ag Lipids and lipid assemblies comprising transfection enhancer elements
ES2535419T3 (es) 2007-12-27 2015-05-11 Protiva Biotherapeutics Inc. Silenciamiento de expresión de quinasa tipo polo usando ARN interferente
FR2926818B1 (fr) * 2008-01-30 2012-04-06 Centre Nat Rech Scient siRNA CATIONIQUES, SYNTHESE ET UTILISATION POUR L'ARN INTERFERENCE
EP2281041B1 (en) 2008-04-15 2014-07-02 Protiva Biotherapeutics Inc. Silencing of csn5 gene expression using interfering rna
JP5588619B2 (ja) 2009-03-11 2014-09-10 一丸ファルコス株式会社 ｐＨ応答性リポソーム
EP3494963A1 (en) * 2009-12-18 2019-06-12 The University of British Columbia Methods and compositions for delivery of nucleic acids
CA2802994A1 (en) 2010-06-17 2011-12-22 The United States Of America As Represented By The Secretary, National I Nstitutes Of Health Compositions and methods for treating inflammatory conditions
MX342608B (es) 2010-07-06 2016-10-06 Novartis Ag * Particulas de suministro similares a viriones para moleculas de arn de autorreplicacion.
ES2646669T3 (es) 2010-07-06 2017-12-14 Glaxosmithkline Biologicals Sa Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
EP2591114B1 (en) 2010-07-06 2016-06-08 GlaxoSmithKline Biologicals SA Immunisation of large mammals with low doses of rna
ES2557382T3 (es) 2010-07-06 2016-01-25 Glaxosmithkline Biologicals Sa Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
LT4226941T (lt) 2010-08-31 2025-01-10 Glaxosmithkline Biologicals Sa Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
WO2012051211A2 (en) 2010-10-11 2012-04-19 Novartis Ag Antigen delivery platforms
US10849975B2 (en) 2011-02-03 2020-12-01 Thomas Jefferson University Multivalent vaccines for rabies virus and filoviruses
WO2012109495A1 (en) 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
US8789967B2 (en) 2011-06-02 2014-07-29 Musco Corporation Apparatus, method, and system for independent aiming and cutoff steps in illuminating a target area
EP2729165B1 (en) 2011-07-06 2017-11-08 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
WO2013032643A2 (en) * 2011-08-31 2013-03-07 Dicerna Pharmaceuticals, Inc. Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells
AU2012340086A1 (en) 2011-11-17 2014-05-29 The Regents Of The University Of California Therapeutic RNA switches compositions and methods of use
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
PL2897620T3 (pl) 2012-09-21 2020-11-02 Intensity Therapeutics, Inc Sposób leczenia nowotworu złośliwego
CA2890725A1 (en) 2012-11-05 2014-05-08 Pronai Therapeutics, Inc. Methods of using biomarkers for the treatment of cancer by modulation of bcl2|expression
JP6339884B2 (ja) 2014-07-17 2018-06-06 富士フイルム株式会社 イミダゾール化合物およびそれを含有するリポソーム
EP3201338B1 (en) 2014-10-02 2021-11-03 Arbutus Biopharma Corporation Compositions and methods for silencing hepatitis b virus gene expression
WO2016197132A1 (en) 2015-06-04 2016-12-08 Protiva Biotherapeutics Inc. Treating hepatitis b virus infection using crispr
WO2017019891A2 (en) 2015-07-29 2017-02-02 Protiva Biotherapeutics, Inc. Compositions and methods for silencing hepatitis b virus gene expression
WO2017040702A1 (en) * 2015-08-31 2017-03-09 The Regents Of The University Of California Bipolar tetraether lipids
US12447166B2 (en) 2016-02-25 2025-10-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
EP3419629A4 (en) 2016-02-25 2019-10-30 Applied Biological Laboratories, Inc. COMPOSITIONS AND PROCEDURES FOR PROTECTION AGAINST AIRBORNE PATHOGENES AND IRRITATES
US11041170B2 (en) 2016-04-04 2021-06-22 Thomas Jefferson University Multivalent vaccines for rabies virus and coronaviruses
EP3500294A4 (en) 2016-08-22 2020-07-29 Arbutus Biopharma Corporation ANTI-PD-1 ANTIBODIES, OR THEIR FRAGMENTS, FOR THE TREATMENT OF HEPATITIS B
US11198831B2 (en) 2019-01-31 2021-12-14 Kvi Llc Lubricant for a device
GB2613225B (en) 2020-03-04 2024-01-03 Verve Therapeutics Inc Compositions and methods for targeted RNA delivery
US20230295199A1 (en) * 2021-03-09 2023-09-21 Nippon Fine Chemical Co., Ltd. Phospholipid
WO2023015223A2 (en) 2021-08-03 2023-02-09 Verve Therapeutics, Inc. Compositions and methods for targeted rna delivery
CN115894281B (zh) * 2021-09-22 2025-07-01 广州谷森制药有限公司 阳离子脂质化合物、其制备方法、组合物及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE45744T1 (de) * 1984-07-25 1989-09-15 Ciba Geigy Ag Phosphatidylverbindungen, verfahren zu ihrer herstellung und ihre verwendung.
CA2032259A1 (en) * 1989-12-18 1991-06-19 Wayne J. Thompson Hiv protease inhibitors useful for the treatment of aids
JP2604268B2 (ja) * 1990-04-09 1997-04-30 富士写真フイルム株式会社 ペプチド誘導体両親媒性化合物、その中間体、ペプチド誘導体両親媒性化合物を用いたリポソームおよび薄膜
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
FR2701396B1 (fr) * 1993-02-12 1995-04-21 Oreal Procédé de stabilisation de vésicules de lipide(s) amphiphile(s) et composition pour application topique contenant lesdites vésicules stabilisées.
KR100283601B1 (ko) * 1993-02-19 2001-03-02 아만 히데아키 글리세롤 유도체, 디바이스 및 의약 조성물
US5354853A (en) * 1993-03-12 1994-10-11 Genzyme Corporation Phospholipid-saccharide conjugates
US5965434A (en) 1994-12-29 1999-10-12 Wolff; Jon A. Amphipathic PH sensitive compounds and delivery systems for delivering biologically active compounds
FR2756565B1 (fr) * 1996-12-04 1998-12-31 Oreal Nouveaux derives d'histidine et leur utilisation en cosmetique ou en pharmacie
JPH11199488A (ja) * 1998-01-09 1999-07-27 Sankyo Co Ltd 抗腫瘍薬のリポソーム化製剤
JPH11217328A (ja) * 1998-01-28 1999-08-10 Nissin Food Prod Co Ltd 抗ｈｉｖ活性を発現する脂質集合体
WO2000030444A1 (en) * 1998-11-25 2000-06-02 Vanderbilt University Cationic liposomes for gene transfer
US7112337B2 (en) 1999-04-23 2006-09-26 Alza Corporation Liposome composition for delivery of nucleic acid
WO2001026625A2 (en) * 1999-10-08 2001-04-19 Alza Corp Neutral-cationic lipid for nucleic acid and drug delivery
DE10109897A1 (de) * 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
DE10109898A1 (de) * 2001-02-21 2002-09-05 Novosom Gmbh Lipide mit veränderlicher Ladung

Similar Documents

Publication Publication Date Title
JP2005526727A5 (https=)
US9387262B2 (en) Coated lipid complexes and their use
KR102299053B1 (ko) Rna 전달을 위한 이온화가능한 양이온성 지질
JP2005517739A5 (https=)
JP7708388B2 (ja) 荷電物質を送達する脂質、その製剤、およびその製造方法
HUT77171A (hu) Lipopoliaminok mint transzfekciós ágensek, és ezeket tartalmazó gyógyászati készítmények
KR20190021218A (ko) 양이온성 지질
CN111417621A (zh) 阳离子脂质
CN121698765A (zh) pH敏感性阳离子性脂质、脂质纳米粒子、含有脂质纳米粒子的医药用组合物以及脂质纳米粒子的用途
EP4709710A1 (en) Ionizable cationic lipids for rna delivery
CN119528753A (zh) 含氮链状化合物、制备方法、包含其的组合物和应用
Le Bolc'h et al. Cationic Phosphonolipids as non Viral Vectors
EP3500552A2 (en) Ph-responsive lipids
JP2021178780A (ja) 末端修飾ポリアミドアミンデンドロン脂質
US7368129B1 (en) Amphiphilic materials and liposome formulations thereof
JP2008303210A (ja) 低級アシル基含有ポリアミドアミンデンドロン脂質
HK40076264A (en) Lipids for delivery of charged material, formulations thereof and method for making same
CN118027129A (zh) 一种可电离脂质化合物及其应用
CN121752256A (zh) 具有核酸负载物和可电离脂质的脂质纳米颗粒
JPWO1999043752A1 (ja) 負電荷物質を輸送するための組成物